Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 ...

Liz Giuffre does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023. It has made several transactions in the past few years to boost its ...